InVitria launches xeno-free formulation service within $5.2bn media market

By InVitria launches xeno-free service within $5.2bn media market

- Last updated on GMT

GettyImages/JVisentin
GettyImages/JVisentin

Related tags: Cell culture media, Cell culture, Cell

Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.

The subsidiary of Ventria Bioscience launched the cell culture media formulation service at the BIO-Europe conference in Berlin, Germany this week, based on its portfolio of supplements made in its completely animal-free system.

“This new service is an extension of the knowledge we have gained in working with our current product line,”​ Randy Alfano, VP of InVitria Product Development, told Biopharma-Reporter. “We have extensive experience in the incorporation of our blood free components into complete media formulations and have already demonstrated success in the market in converting manufacturing processes to be blood free.”

The firm is offering access to its animal component free cell culture media formulations to preclinical and early-phase clinical firms developing stem cell, immunotherapies, and novel vaccines.

“Every media formulation we develop is completely void of any animal or human-serum derived components, a type of cell culture media that we refer to as ‘Blood Free.’ Further, these media are void of any undefined substances such as plant hydrolysates.”

Rise of animal-free media

InVitria estimates the total mammalian cell culture market to around 30 million liters annually, which is worth around $5.2bn. And according to Alfano xeno-free serums are taking an increasingly larger percentage of that market.

“We believe that recombinant protein expression technology and knowledge in media development has essentially progressed to the point that inclusion of serum or serum-derived proteins is an obsolete approach that has an unacceptable risk in terms of patient safety.”

InVitria is one of a number of firms offering xeno-free options to cell therapy and biopharma firms.

Over the past couple of years, Corning​, Irvine Scientific​, Evercyte​ and Worthing​ have all upped their presence in the space.

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars